Introduction
Chronic kidney disease (CKD) is said to have a strong effect on the prognosis of cardiovascular disease. 1, 2) 6,668 CABG patients, 6 .4% for 4,836 percutaneous transluminal coronary angioplasty (PTCA) patients, and 4.1% for 4,280 stent patients and the 2-year all-cause survival rate was 56.4% for CABG patients, 48.2% for PTCA patients, and 48.4% for stent patients. Dialysis patients had better long-term survival after CABG than after percutaneous coronary intervention. 5) Most published studies of CABG for dialysis patients only provide short-term results, and reports of the longterm outcome are rare. Therefore, the formulation of a new treatment strategy for dialysis patients is an urgent necessity. We examined the early and long-term outcome of CABG for dialysis patients in the present study.
Patients and Methods
Ninety patients underwent CABG for dialysis patients at Nihon University Itabashi Hospital between April 2001 and March 2010. If possible, surgical procedures were performed under cardiopulmonary bypass (CPB). CPB was performed with nonpulsatile mild hypothermic perfusion. Three consult cardiac surgeons performed the operations. For elective surgery, dialysis was performed on the day before surgery. Hemofiltration was performed during surgery in all patients and dialysis was started again postoperatively 1 or 2 days after surgery.
The preoperative factors examined were an age ≥75 years, gender, acute myocardial infarction (AMI), lesions of the main trunk of the left coronary artery, emergent (within 24h of onset), preoperative intra-aortic balloon pump (IABP) assist, previous percutaneous coronary intervention, ejection fraction (EF) <40%, diabetes mellitus, hypertension, dyslipidemia, obesity, smoking, cerebrovascular disease, peripheral artery disease (PAD), and duration of dialysis. Intraoperative factors examined were use of the LITA, concomitant surgery, complete revascularization, residual disease, aortic cross clamping time ≥90 min extracorporeal circulation time ≥180 min, and intraoperative commencement of human atrial natriuretic peptide (hANP) (carperitide, Daiichi-Sankyo Pharmaceutical Inc., Tokyo, Japan and Asubio Pharmaceuticals, Inc., Kobe, Japan) therapy (NU-HIT trial; Clinical trials registry: University Hospital Medical Information Network (UMIN); Trial Number: UMIN000001461). We examined early death, complications, and major adverse cardiovascular and cerebrovascular event (MACCE). Logistic regression analysis was conducted using preoperative and intraoperative factors in relation to the early death and MACCE.
At our hospital, we are presently conducting a randomised controlled trial (RCT) of intraoperative administration of hANP therapy, and subjects from that trial are included in this study.
This was a retrospective study with a 100% follow-up rate, and a mean follow-up period of 3.4 ± 2.5 years (maximum 10.0 years).
Statistical analysis
Data are expressed as the mean ± the standard deviations (SD). For statistical analysis, univariate logistical regression analysis of the pre-and intra-operative factors was performed. Variables showing significance were then subjected to multivariate analysis. The overall mortality rate, cardiovascular mortality rate, and postoperative cardiovascular event-free rate were determined by the Kaplan-Meier method. Student's t-test and Fisher's exact test were used for other statistical analyses. A probability (p) value of less than 0.05 was considered to indicate statistical significance.
Results
Preoperative background and intraoperative and postoperative factors of the 90 patients are summarized in (Table 1) .
Operative mortality and early complications
The overall operative mortality rate was 8.9% (n = 8) and the operative mortality was 6.9% (n = 5) for patients having isolated CABG and 16.7% (n = 3) for patients having concomitant surgery (p = 0.1951). Deaths in cases of isolated CABG all occurred in patients who underwent emergency operations under IABP assist preoperatively. The cause of death was low output syndrome (LOS) and postoperative bleeding in 2 cases each, arrhythmia, multiple organ failure (MOF), mediastinitis, and pneumonia in 1 case each. The perioperative complication occurred in 18 patients. The cause of complication was bleeding in 5 cases (bleeding in surgical site in 4 patients and gastrointestinal bleeding in 1 case), LOS in 3 patients, mediastinitis, ventricular tachycardia, and wound infection in 2 cases each, and heart failure, MOF, pneumonia, and perioperative myocardial infarction in 1 case each. Postoperative atrial fibrillation occurred in 21 patients and transient disturbance of consciousness in 10 patients.
Late results and MACCE
There were 14 late deaths, with the cause being sudden death in 4 cases, heart failure in 4 cases, gastrointestinal bleeding in 2 cases, ischemic heart disease, cerebral infarction, pneumonia, and infection of PAD in 1 case each. MACCE was confirmed in 30 patients and 22 patients died [heart failure in 6 patients (including two cases of LOS), four sudden deaths, four with bleeding, two with pneumonia and one each with ischemic heart disease, arrhythmia, cerebral infarction, MOF, mediastinitis and infection of PAD]. Heart failure occurred in four cases (including one case of LOS), and one case each of recurrence of ischemic heart disease, treatment-resistant arrhythmia cerebral infarction and cerebral hemorrhage were recorded. Three patients for whom concomitant operations were not performed and who had residual disease all died after discharge. The postoperative 1-year survival rate was 81.5 ± 18.5%, the 5-year survival rate was 72.0 ± 28.0%, and the 8-year survival rate was 68.4 ± 31.6% (Fig. 1) . The postoperative MACCE event-free rate was 70.3 ± 29.7% at 1 year, 61.8 ± 38.2% at 5 years, and 58.6 ± 41.4% at 8 years ( Fig. 1) .
Late results and MACCE were compared by operative method (isolated CABG and concomitant surgery). For isolated CABG, the postoperative 1-year survival rate was 88.8 ± 3.7% and the 5-year survival rate was 73.6 ± 6.3%. For concomitant surgery, the postoperative 1-year survival rate was 77.4 ± 10.0%, the 5-year survival rate was 70.9 ± 11.0%, and the 8-year survival rate 68.4 ± 31.6%. No significant differences between operative methods were observed (p = 0.1017). The postoperative MACCE event-free rate for isolated CABG was 81.8 ± 4.6% at 1 year and 62.5 ± 6.5% at 5 years, while for concomitant surgery, the rate was 72.2 ± 10.6% at 1 year and 66.2 ± 11.3% at 5 years. No significant differences between operative methods were observed (p = 0.2566) (Fig. 2) .
Analysis of the early all cause death revealed the following risk factors (Table 2) Univariate analysis confirmed that AMI, age ≥75 years, preoperative IABP assist, concomitant surgery, and non-use hANP therapy were risk factors. Multivariate analysis confirmed that preoperative IABP assist, concomitant surgery, and non-use hANP therapy were risk factors. 
Discussion
The early and long-term results for dialysis patients undergoing CABG were not satisfactory. Advanced age, female, need for a preoperative IABP, and use of CPB, EF <40%, and concomitant surgery, incomplete revascularization were reported as a risk factor of early death for dialysis patients undergoing CABG. In present study, we identified AMI, age ≥75 years, preoperative IABP assist, concomitant surgery, and non-use hANP therapy as risk factors for early death and EF <40%, preoperative IABP assist, and non-use of hANP therapy as risk factors for postoperative MACCE. Furthermore, we considered that prevent of postoperative bleeding, infection in early stage and heart failure, cerebral infarction, and progression of PAD are important. Yamamura, et al. reported that the hospital mortality rate for those underwent concomitant aortic valve replacement (AVR) plus CABG was 33.3% and the 1-year survival rate of concomitant AVR plus CABG was significantly poorer (21%, P <0.01) than those of isolated CABG only (92%). 6) Concomitant surgery is a significant risk factor for mortality following cardiac surgery in dialysis patients. Although a concomitant surgery was one of risk factors for early death, three patients for whom concomitant operations were not performed and who had residual disease all died in this study. Therefore, since the patients who did not undergo concomitant operations all died in the long-term because of residual disease, measures related to concomitant surgery are a subject for future study.
As for mid-and long-term results of dialysis patients undergoing CABG in previous reports, the overall 1-, 5-, 7-year survival rates were 68.6%-84.7% and 35.4%-63.7%, 35.4%, respectively, and the actual cardiac-event-free rate 1, 5, and 7 years after CABG were 77.6%, 46.6%-51.7%, and 46.6%, respectively. 8-10) Sunagawa, et al. examined for 29 Japanese dialysis patients undergoing CABG, they reported that the 30-day mortality was 3.3%, the 2-year survival rate was 84.0%, and the major adverse cardiac events-free rate at 2 years was 75.8%. 4) We considered that our results were acceptable.
In present study, non-use of hANP was a significant risk factor for early death and MACCE. Although in-hospital deaths in patients with use of hANP therapy was 1 case, 7 patients died in patients with non-use of hANP therapy (p = 0.0582). We previously performed the first randomized controlled trial of hANP therapy commenced intraoperatively, which showed this treatment suppresses the renin-angiotensin-aldosterone system, inhibits left ventricular remodelling, prevents ischemia-reperfusion injury, and has renoprotective and cardioprotective effects. [11] [12] [13] On a randomized controlled study of 303 non-dialysis patients with CKD who underwent CABG, significantly fewer patients had postoperative cardiac events in the hANP group and the postoperative dialysis-free rate was significantly higher in the hANP group. 14) No studies on efficacy of hANP in AMI: acute myocardial infarction; IABP: intra aortic balloon pump; PCI: peripheral coronary intervention; LITA: left internal thoracic artery; ACCT: aortic cross clamping time; ECCT: extracorporeal circulating time; hANP: human atrial natriuretic peptide dialysis patients have been reported. For dialysis patients with very severe renal dysfunction, hANP has no meaning as an agent for renoprotective effects. However, from this research, it appeared possible to prevent the onset of MACCE not only in terms of early postoperative results but also in the long-term by utilizing cardioprotective effects. J-WIND (Japan Working groups of acute myocardial Infarction for the reduction of Necrotic Damage) trial and our past studies demonstrated that perioperative therapy with hANP could improve long-term prognosis. 12, 14, 15) Although the mechanism of action behind such a long-term effect is not fully elucidated, we speculate from the result of the past studies that hANP does not inhibit RAAS which rapidly increases due to the influence of artificial heart-lung system, and specifically prevent left ventricular remodeling by strongly inhibiting aldosterone during the ultra-acute phase, thereby preventing transition of post-operative heart failure to chronic phase. This is of interest in dialysis patients whose chronic outcome is poor and we would like to clarify the effectiveness in those patients.
Comparative studies on on-pump CABG and off pump CABG (OPCAB) as surgical methods for dialysis patients have been reported. Many reports indicate that OPCAB is better than on-pump CABG in terms of early results, but there is no difference in long-term results. 3, [16] [17] [18] Shroff, et al. found in a survey of 13,085 patients on dialysis in the USRDS database that estimated all-cause survival rates were significantly higher for OPCAB at 30 days postoperatively, but no differences were reported between OPCAB and on-pump CABG after 6 months, and 1, 2 and 3 years. 18) Past reports have all been on surveys from various databases or retrospective studies in single-center. RCT on OPCAB and on-pump CABG in dialysis patients have still not been reported. In our institute, on-pump CABG is basically used for all CABG. The reason for this is that it has been verified from the results of RCTs on the low-dose hANP therapy method from during surgery in patients other than dialysis patients that hANP has effects that compensate for CPB defects (RAAS inhibitory effects, strong cardioprotective effects, etc.). However, the present study was a retrospective study and assessments by RCTs are important to indicate the efficacy of the hANP more clearly. We are performing randomized control trials on hANP (trial number: UMIN000001461), for dialysis patients undergoing cardiac surgery and will report the results when the targeted numbers of patients are reached in the future. From these results, the efficacy of postoperative hANP therapy in dialysis patients undergoing cardiac surgery should be clearer.
Limitations
From this study, it was evident that hANP administration during surgery is one factor for good prognosis, but this was a retrospective study. Currently a randomized controlled trial is in progress and this point should be clarified in the future. In CABG in many dialysis patients with valvular disease as a complication, we want most to verify whether operations should be performed at the same time on the complicating diseases. When the number of patients is increased in the future, they should be divided into an isolated CABG group, CABG + concomitant surgery group and a group that should have been given concomitant surgery but only underwent CABG, and the early and later effects in the three groups should be investigated.
